Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Peptidoglycan degrading enzymes are of increasing interest as antibacterial agents, especially against multi-drug resistant pathogens. Herein we present a review about the biological features of virion-associated lysins and endolysins, phage-derived enzymes that have naturally evolved to compromise the bacterial peptidoglycan from without and from within, respectively. These natural features may determine the adaptability of the enzymes to kill bacteria in different environments. Endolysins are by far the most studied group of peptidoglycan-degrading enzymes, with several studies showing that they can exhibit potent antibacterial activity under specific conditions. However, the lytic activity of most endolysins seems to be significantly reduced when tested against actively growing bacteria, something that may be related to fact that these enzymes are naturally designed to degrade the peptidoglycan from within dead cells. This may negatively impact the efficacy of the endolysin in treating some infections in vivo. Here, we present a critical view of the methods commonly used to evaluate in vitro and in vivo the antibacterial performance of PG-degrading enzymes, focusing on the major hurdles concerning in vitro-to-in vivo translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Peptidoglycan types of bacterial cell walls and their taxonomic implications
Schleifer, K. H., & Kandler, O. (1972) · Bacteriological Reviews · doi:10.1128/mmbr.36.4.407-477.1972 · Cited by 4,223
Peptidoglycan types of bacterial cell walls and their taxonomic implications
Schleifer, K. H., & Kandler, O. (1972) · Bacteriological Reviews · doi:10.1128/br.36.4.407-477.1972 · Cited by 4,222
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931 · cited 1×
“ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and other Enterobacteriaceae species) are the leading group among these so-called superbugs, that can rapidly gain resistances to several classes of antibiotics and are able to cause a…”
BackgroundEstimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002
Klevens, R. M., Edwards, J. R., Richards, C. L., Horan, T. C., Gaynes, R. P., Pollock, D. A., & Cardo, D. M. (2007) · Public Health Reports® · doi:10.1177/003335490712200205 · Cited by 2,960 · cited 1×
“ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and other Enterobacteriaceae species) are the leading group among these so-called superbugs, that can rapidly gain resistances to several classes of antibiotics and are able to cause a…”
BackgroundPeptidoglycan structure and architecture
Vollmer, W., Blanot, D., & De Pedro, M. A. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2007.00094.x · Cited by 2,340 · cited 1×
“Adjacent glycan strands are cross-linked by short interconnected stem peptides, each of them linked to MurNAc residues through an amide bond involving the first amino acid of the peptide stem (usually L-alanine [17]).”
BackgroundCeri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155 · cited 1×
“Variations of this assay include the minimum bactericidal concentration and the minimum biofilm eradication concentration, for determination of the minimum concentrations leading to undetectable CFUs after targeting suspended and sessile cultures, respectively [75,76].”
MethodFrom the regulation of peptidoglycan synthesis to bacterial growth and morphology
Typas, A., Banzhaf, M., Gross, C. A., & Vollmer, W. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2677 · Cited by 1,273 · cited 1×
“It is known that PG maturation and remodeling occurs in stationary cells and can involve the acetylation and/or N-deacetylation of glycan chains and amidation of peptides, modifications that may confer resistance to lytic enzymes [117].”
BackgroundBacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785 · cited 1×
“Phage-encoded enzymes that have the capacity to degrade the major component of the bacterial cell wall (CW), the peptidoglycan (PG), or murein, represent a promising alternative class of antibacterial agents with increasing prominence [8,9].”
BackgroundTsai, C. J.-Y., Loh, J. M. S., & Proft, T. (2016) · Virulence · doi:10.1080/21505594.2015.1135289 · Cited by 778
Troeger, C., Forouzanfar, M., Rao, P. C., Khalil, I., Brown, A., Swartz, S., Fullman, N., Mosser, J., Thompson, R. L., Reiner, R. C., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30396-1 · Cited by 764
A bacteriolytic agent that detects and kills Bacillus anthracis
Schuch, R., Nelson, D., & Fischetti, V. A. (2002) · Nature · doi:10.1038/nature01026 · Cited by 656 · cited 1×
“aureus [45,54,94–107], Bacillus anthracis [108,109] and E.”
Nelson, D., Loomis, L., & Fischetti, V. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061038398 · Cited by 578 · cited 2×
“Almost two decades after the first experimental validation of their antibacterial potential [10], we present the biological, molecular and antibacterial properties of the different phage-derived PG-degrading enzymes and highlight some advantages, constraints”
BackgroundRapid Killing of Streptococcus pneumoniae with a Bacteriophage Cell Wall Hydrolase
Loeffler, J. M., Nelson, D., & Fischetti, V. A. (2001) · Science · doi:10.1126/science.1066869 · Cited by 517
Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens
Fischetti, V. A. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.002 · Cited by 438 · cited 1×
“While phage-derived PG-degrading enzymes have been shown to efficiently work exogenously as recombinant proteins to kill Gram-positive bacteria pathogens (for extensive review see [61]), their application against Gram-negative pathogens is more limited.”
BackgroundEngineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens
Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., Oliveira, H., Azeredo, J., Verween, G., Pirnay, J.-P., et al. (2014) · mBio · doi:10.1128/mbio.01379-14 · Cited by 421 · cited 5×
“Artilysins (e.g., LoGT-008) have also been successfully applied in human keratinocytes and Caenorhabditis elegans models to control infections [67].”
BackgroundInfluentialSelf-citationLatka, A., Maciejewska, B., Majkowska-Skrobek, G., Briers, Y., & Drulis-Kawa, Z. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8224-6 · Cited by 376
Nelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., & Donovan, D. M. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00007-4 · Cited by 372 · cited 3×
“For example, for reasons that are still unknown, some enzymes with high bacteriolytic activity seem not amenable to standard MIC determinations [8,70].”
BackgroundLoessner, M. J., Kramer, K., Ebel, F., & Scherer, S. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02889.x · Cited by 367 · cited 1×
“The most accepted hypothesis for the presence of CBD in most endolysins of phages infecting Gram-positive hosts, is that by being bound to the CW debris after cell lysis, the enzymes will not diffuse and destroy nearby potential hosts, therefore enabling progeny phages to initiate new infection rounds [23].”
BackgroundTHE GROWTH OF BACTERIOPHAGE AND LYSIS OF THE HOST
Delbrück, M. (1940) · Journal of General Physiology · doi:10.1085/jgp.23.5.643 · Cited by 300 · cited 1×
“VALs lytic activity is responsible for the “lysis from without” phenomenon, first described in 1940, due to multiple phages puncturing [29].”
BackgroundThe non‐enzymatic microbicidal activity of lysozymes
Düring, K., Porsch, P., Mahn, A., Brinkmann, O., & Gieffers, W. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00405-6 · Cited by 291 · cited 2×
“Although the OM of Gram-negative bacteria is generally viewed as a barrier that blocks access to the CW of exogenously-added enzymes, several examples of endolysins that spontaneously cross the OM and exert lytic activity were reported [21,62,63,119,120].”
BackgroundMolecular Aspects and Comparative Genomics of Bacteriophage Endolysins
Oliveira, H., Melo, L. D. R., Santos, S. B., Nóbrega, F. L., Ferreira, E. C., Cerca, N., Azeredo, J., & Kluskens, L. D. (2013) · Journal of Virology · doi:10.1128/jvi.03277-12 · Cited by 288 · cited 4×
“Endolysins can have a globular or a modular design [18,19].”
BackgroundInfluentialSelf-citationPhage lysis: do we have the hole story yet?
Young, R. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.08.008 · Cited by 274 · cited 1×
“Once in this cell compartment, endolysins quickly degrade the PG polymers of the killed host bacteria, leading to abrupt osmotic cell lysis and subsequent release of progeny phages [15,16].”
BackgroundLood, R., Winer, B. Y., Pelzek, A. J., Diez-Martinez, R., Thandar, M., Euler, C. W., Schuch, R., & Fischetti, V. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04641-14 · Cited by 272 · cited 2×
“baumannii resulted in 50% of survival compared with the 10% of survival of the control group [112].”
BackgroundResultPhage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal Bacteremia
Loeffler, J. M., Djurkovic, S., & Fischetti, V. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.11.6199-6204.2003 · Cited by 269 · cited 1×
“In one study, 100% Cpl-1-treated mice survived when Cpl-1 was added intravenously 1 h-postinfection [73].”
Diversity in bacterial lysis systems: bacteriophages show the way
Catalão, M. J., Gil, F., Moniz-Pereira, J., São-José, C., & Pimentel, M. (2013) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12006 · Cited by 252 · cited 1×
“Once in this cell compartment, endolysins quickly degrade the PG polymers of the killed host bacteria, leading to abrupt osmotic cell lysis and subsequent release of progeny phages [15,16].”
BackgroundSelf-citationO'Flaherty, S., Coffey, A., Meaney, W., Fitzgerald, G. F., & Ross, R. P. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.20.7161-7164.2005 · Cited by 234 · cited 1×
“aureus (endolysins LysK and MV-L, respectively) [45,46], and towards vancomycin-resistant E.”
BackgroundYoong, P., Schuch, R., Nelson, D., & Fischetti, V. A. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.14.4808-4812.2004 · Cited by 233
Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., & Fischetti, V. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01625-09 · Cited by 233 · cited 2×
“In the case of staphylococcal phage endolysins, similar modifications were made to overcome solubility problems [53,54].”
BackgroundCheng, Q., Nelson, D., Zhu, S., & Fischetti, V. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.111-117.2005 · Cited by 233
Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., Yagyu, K., Muraoka, A., Sugai, M., Hiramatsu, K., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/521305 · Cited by 232 · cited 1×
“aureus (endolysins LysK and MV-L, respectively) [45,46], and towards vancomycin-resistant E.”
BackgroundJado, I. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg485 · Cited by 216 · cited 2×
“pneumoniae strains have been targeted using Cpl-1 and Pal endolysins, which share the same target specificity but have different catalytic activities [48].”
BackgroundMethodGilmer, D. B., Schmitz, J. E., Euler, C. W., & Fischetti, V. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02526-12 · Cited by 216
Lai, M., Lin, N., Hu, A., Soo, P., Chen, L., Chen, L., & Chang, K. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3104-y · Cited by 214 · cited 1×
“Although the OM of Gram-negative bacteria is generally viewed as a barrier that blocks access to the CW of exogenously-added enzymes, several examples of endolysins that spontaneously cross the OM and exert lytic activity were reported [21,62,63,119,120].”
BackgroundPeptidoglycan hydrolytic activities associated with bacteriophage virions
Moak, M., & Molineux, I. J. (2004) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03894.x · Cited by 210 · cited 3×
“At the beginning of phage infection, VALs attack the CW of host cells from outside and are thought to promote a local degradation of the murein to facilitate penetration of the phage tail tube and injection of the viral DNA [12].”
BackgroundOliveira, H., Thiagarajan, V., Walmagh, M., Sillankorva, S., Lavigne, R., Neves-Petersen, M. T., Kluskens, L. D., & Azeredo, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108376 · Cited by 207 · cited 2×
“In the case of Gram-negative species, an additional step involving treatment with chloroform vapors is needed to permeabilize the OM [65].”
BackgroundSelf-citationBriers, Y., Walmagh, M., Grymonprez, B., Biebl, M., Pirnay, J.-P., Defraine, V., Michiels, J., Cenens, W., Aertsen, A., Miller, S., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02668-14 · Cited by 200 · cited 2×
“, SMAP-29 and polycationic nonapeptide), to allow passage of the recombinant proteins through the OM [67,68].”
BackgroundBriers, Y., Volckaert, G., Cornelissen, A., Lagaert, S., Michiels, C. W., Hertveldt, K., & Lavigne, R. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05870.x · Cited by 197 · cited 1×
“Nevertheless, few exceptions with modular structure have been reported in Gram-negative systems but, interestingly, with inverted orientation of the functional domains [21,22].”
BackgroundSchuch, R., Lee, H. M., Schneider, B. C., Sauve, K. L., Law, C., Khan, B. K., Rotolo, J. A., Horiuchi, Y., Couto, D. E., Raz, A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit637 · Cited by 196
Synthetic biology of modular endolysins
Gerstmans, H., Criel, B., & Briers, Y. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.12.009 · Cited by 195 · cited 2×
“The fact that endolysins when applied systemically could face short half-life, immunogenicity, allergenicity, proinflammatory responses and inability to target intracellular bacteria is well discussed elsewhere [50].”
BackgroundBriers, Y., & Lavigne, R. (2015) · Future Microbiology · doi:10.2217/fmb.15.8 · Cited by 189
Pastagia, M., Euler, C., Chahales, P., Fuentes-Duculan, J., Krueger, J. G., & Fischetti, V. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00890-10 · Cited by 188
Gu, J., Xu, W., Lei, L., Huang, J., Feng, X., Sun, C., Du, C., Zuo, J., Li, Y., Du, T., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01144-10 · Cited by 174 · cited 1×
“single doses of LysGH15 (50 μg/mouse) were sufficient to protect mice against lethal systemic MRSA infections [103,116].”
BackgroundBacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics
Rodríguez-Rubio, L., Martínez, B., Donovan, D. M., Rodríguez, A., & García, P. (2013) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2012.723675 · Cited by 173 · cited 1×
“The absence of CBDs in VALs could be explained by the fact that they are often subdomains of larger proteins or belong to virion structures that promote proximity of the VAL to the CW [26].”
BackgroundEngineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials
São‐José, C. (2018) · Antibiotics · doi:10.3390/antibiotics7020029 · Cited by 171
Self-citationLysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells
Becker, S. C., Dong, S., Baker, J. R., Foster-Frey, J. A., Pritchard, D. G., & Donovan, D. M. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01541.x · Cited by 169 · cited 3×
“Lysis is measured as a decrease of optical density over time which can be assessed by i) the steepest slope of the killing curve (i.e., unit is defined by ∆OD/min) [70,72] or by quantification of the amount of protein necessary to drop a percentage of the optical density relative to its initial value (i.e., unit is de…”
BackgroundCharacterization of Modular Bacteriophage Endolysins from Myoviridae Phages OBP, 201φ2-1 and PVP-SE1
Walmagh, M., Briers, Y., Santos, S. R. B., Azeredo, J., & Lavigne, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036991 · Cited by 169 · cited 3×
“Although the OM of Gram-negative bacteria is generally viewed as a barrier that blocks access to the CW of exogenously-added enzymes, several examples of endolysins that spontaneously cross the OM and exert lytic activity were reported [21,62,63,119,120].”
BackgroundSelf-citationThumm, G., & Götz, F. (1997) · Molecular Microbiology · doi:10.1046/j.1365-2958.1997.2911657.x · Cited by 165 · cited 1×
“Interestingly, this domain is responsible for the PG-degrading activity of the bacteriolysins lysostaphin and enterolysin A [24,25], which also act from without and on actively growing cells.”
BackgroundLow, L. Y., Yang, C., Perego, M., Osterman, A. L., & Liddington, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.244160 · Cited by 164
Schmelcher, M., Shen, Y., Nelson, D. C., Eugster, M. R., Eichenseher, F., Hanke, D. C., Loessner, M. J., Dong, S., Pritchard, D. G., Lee, J. C., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku552 · Cited by 160
Deaths: Leading Causes for 2015.
Heron, M. P. (2017) · PubMed · Cited by 159
Briers, Y., Walmagh, M., & Lavigne, R. (2011) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2010.04931.x · Cited by 159
Oliveira, H., Vilas Boas, D., Mesnage, S., Kluskens, L. D., Lavigne, R., Sillankorva, S., Secundo, F., & Azeredo, J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00208 · Cited by 157
Self-citationRapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin
Shen, Y., Köller, T., Kreikemeyer, B., & Nelson, D. C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt104 · Cited by 155 · cited 1×
“Variations of this assay include the minimum bactericidal concentration and the minimum biofilm eradication concentration, for determination of the minimum concentrations leading to undetectable CFUs after targeting suspended and sessile cultures, respectively [75,76].”
MethodHorgan, M., O’Flynn, G., Garry, J., et al. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.01831-08 · Cited by 151 · cited 1×
“aureus phage LysK and Streptococcus agalactiae PlyGBS endolysins resulted in 2and ~25-fold increase in muralytic activity, respectively [55,56].”
BackgroundEntenza, J. M., Loeffler, J. M., Grandgirard, D., Fischetti, V. A., & Moreillon, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4789-4792.2005 · Cited by 150
Moak, M., & Molineux, I. J. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01995.x · Cited by 139 · cited 2×
“coli phage T7 showed to be dispensable for phage infection in the lab suggests that they may confer an advantage only under certain physiological conditions [13,14].”
BackgroundChimeric phage-bacterial enzymes: a clue to the modular evolution of genes.
Dı́az, E., López, R., & García, J. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.20.8125 · Cited by 139 · cited 1×
“It was shown that ECDs and CBDs from different enzymes could be exchanged to generate chimeras that retained the native cleavage and binding properties of the individual modules [52].”
BackgroundMycobacteriophage Endolysins: Diverse and Modular Enzymes with Multiple Catalytic Activities
Payne, K. M., & Hatfull, G. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034052 · Cited by 138 · cited 1×
“This modular configuration is most commonly found in endolysins of phages infecting Gram-positive bacteria and mycobacteria [8,18,20].”
BackgroundSystemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia*
Witzenrath, M., Schmeck, B., Doehn, J. M., Tschernig, T., Zahlten, J., Loeffler, J. M., Zemlin, M., Müller, H. C., Gutbier, B., Schütte, H., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819586a6 · Cited by 136
Díez‐Martínez, R., de Paz, H. D., García‐Fernández, E., Bustamante, N., Euler, C. W., Fischetti, V. A., Menéndez, M., & García, P. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv038 · Cited by 133 · cited 2×
“In a second independent study, only about 30% Cpl-1-treated mice survived when the enzyme was added intraperitoneally 1 h-post infection [78].”
BackgroundMayer, M. J., Garefalaki, V., Spoerl, R., Narbad, A., & Meijers, R. (2011) · Journal of Bacteriology · doi:10.1128/jb.00439-11 · Cited by 126
Cheng, Q., & Fischetti, V. A. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-006-0771-1 · Cited by 120 · cited 1×
“aureus phage LysK and Streptococcus agalactiae PlyGBS endolysins resulted in 2and ~25-fold increase in muralytic activity, respectively [55,56].”
BackgroundDíez‐Martínez, R., de Paz, H. D., Bustamante, N., García, E., Menéndez, M., & García, P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01372-13 · Cited by 119
STUDIES OF L FORMS AND PROTOPLASTS OF GROUP A STREPTOCOCCI
Freimer, E. H., Krause, R. M., & McCarty, M. (1959) · The Journal of Experimental Medicine · doi:10.1084/jem.110.6.853 · Cited by 118
Heo, Y.-J., Lee, Y.-R., Jung, H.-H., Lee, J., Ko, G., & Cho, Y. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01646-08 · Cited by 116
Djurkovic, S., Loeffler, J. M., & Fischetti, V. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1225-1228.2005 · Cited by 114
Identification and characterization of a highly thermostable bacteriophage lysozyme
Lavigne, R., Briers, Y., Hertveldt, K., Robben, J., & Volckaert, G. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4301-y · Cited by 113 · cited 2×
“Moreover, ECDs from VALs may present increased thermostability when compared to those derived from endolysins [32,37,42,71], which may result in prolonged shelf life.”
BackgroundMethodNovel Strategy to Prevent Otitis Media Caused by Colonizing Streptococcus pneumoniae
McCullers, J. A., Karlström, Å., Iverson, A. R., Loeffler, J. M., & Fischetti, V. A. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030028 · Cited by 110
Yang, H., Linden, S. B., Wang, J., Yu, J., Nelson, D. C., & Wei, H. (2015) · Scientific Reports · doi:10.1038/srep17257 · Cited by 110
Phage Lytic Enzyme Cpl‐1 for Antibacterial Therapy in Experimental Pneumococcal Meningitis
Grandgirard, D., Loeffler, J. M., Fischetti, V. A., & Leib, S. L. (2008) · The Journal of Infectious Diseases · doi:10.1086/587942 · Cited by 106
Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus
Becker, S. C., Roach, D. R., Chauhan, V. S., Shen, Y., Foster-Frey, J. A., Powell, A. M., Bauchan, G. R., Lease, R. A., Mohammadi, H., Harty, W. J., et al. (2016) · Scientific Reports · doi:10.1038/srep25063 · Cited by 106 · cited 1×
“Recent developments have also uncovered the potential of engineered, phage-derived lytic enzymes to target intracellular pathogens [95,127].”
BackgroundGlavis‐Bloom, J., Muhammed, M., & Mylonakis, E. E. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5638-5_2 · Cited by 106
Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1
Jun, S. Y., Jung, G. M., Yoon, S. J., Oh, M., Choi, Y., Lee, W. J., Kong, J.-C., Seol, J. G., & Kang, S. H. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.011 · Cited by 105
Peng, S.-Y., You, R.-I., Lai, M.-J., Lin, N.-T., Chen, L.-K., & Chang, K.-C. (2017) · Scientific Reports · doi:10.1038/s41598-017-11832-7 · Cited by 105
Singh, P. K., Donovan, D. M., & Kumar, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00126-14 · Cited by 103 · cited 1×
“Ply187-derived chimeolysins tested in vivo include Ply187AN-KSH3b, ClyH and ClyF [94,101,114,115].”
BackgroundThe truncated phage lysin CHAPkeliminatesStaphylococcusaureusin the nares of mice
Fenton, M., Casey, P. G., Hill, C., Gahan, C. G. M., McAuliffe, O. E., Mahony, J. O., Maher, F., & Coffey, A. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13422 · Cited by 100
Yoong, P., Schuch, R., Nelson, D. C., & Fischetti, V. A. (2006) · Journal of Bacteriology · doi:10.1128/jb.188.7.2711-2714.2006 · Cited by 98 · cited 1×
“aureus [45,54,94–107], Bacillus anthracis [108,109] and E.”
Rodríguez‐Rubio, L., Martínez, B., Rodríguez, A., Donovan, D. M., & García, P. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.07621-11 · Cited by 96 · cited 1×
“Additionally, VALs have been shown to synergize with endolysins and antibiotics [39,40].”
BackgroundBacteriophage endolysins as a response to emerging foodborne pathogens
Oliveira, H., Azeredo, J., Lavigne, R., & Kluskens, L. (2012) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2012.06.016 · Cited by 94 · cited 1×
“Endolysins can have a globular or a modular design [18,19].”
BackgroundSelf-citationPaul, V. D., Rajagopalan, S. S., Sundarrajan, S., George, S. E., Asrani, J. Y., Pillai, R., Chikkamadaiah, R., Durgaiah, M., Sriram, B., & Padmanabhan, S. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-226 · Cited by 91
Yang, H., Zhang, H., Wang, J., Yu, J., & Wei, H. (2017) · Scientific Reports · doi:10.1038/srep40182 · Cited by 88 · cited 1×
“Ply187-derived chimeolysins tested in vivo include Ply187AN-KSH3b, ClyH and ClyF [94,101,114,115].”
BackgroundYang, H., Wang, M., Yu, J., & Wei, H. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01471 · Cited by 85 · cited 1×
“Yet, it was completely inactive when tested in biomatrixes such as pasteurized milk, human serum and different bacterial culture media [122].”
BackgroundStockdale, S. R., Mahony, J., Courtin, P., Chapot-Chartier, M.-P., van Pijkeren, J.-P., Britton, R. A., Neve, H., Heller, K. J., Aideh, B., Vogensen, F. K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444901 · Cited by 85 · cited 3×
“In Gram-positive hosts, VALs from lactococcal phages Tuc2009 and TP901-1 and Bacillus subtilis phages SP-β and phi29 were tested and proved to degrade the bacterial CW [30,31].”
BackgroundResultAntimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus
Manoharadas, S., Witte, A., & Bläsi, U. (2008) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2008.09.003 · Cited by 81
Yang, H., Zhang, Y., Yu, J., Huang, Y., Zhang, X., & Wei, H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01793-13 · Cited by 79 · cited 1×
“Ply187-derived chimeolysins tested in vivo include Ply187AN-KSH3b, ClyH and ClyF [94,101,114,115].”
BackgroundBecker, S. C., Swift, S. M., Korobova, O. V., Schischkova, N., Kopylov, P. K., Donovan, D. M., & Abaev, I. (2015) · FEMS Microbiology Letters · doi:10.1093/femsle/fnu019 · Cited by 77
A bacteriophage endolysin that eliminates intracellular streptococci
Shen, Y., Barros, M., Vennemann, T., Gallagher, D. T., Yin, Y., Linden, S. B., Heselpoth, R. D., Spencer, D. J., Donovan, D. M., Moult, J., et al. (2016) · eLife · doi:10.7554/elife.13152 · Cited by 75 · cited 1×
“Recent developments have also uncovered the potential of engineered, phage-derived lytic enzymes to target intracellular pathogens [95,127].”
BackgroundDelivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia
Doehn, J.-M., Fischer, K., Reppe, K., Gutbier, B., Tschernig, T., Hocke, A., Fischetti, V. A., Loffler, J., Suttorp, N., Hippenstiel, S., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt131 · Cited by 73
Fernandes, S., Proença, D., Cantante, C., Silva, F. A., Leandro, C., Lourenço, S., Milheiriço, C., de LENCASTRE, H., Cavaco‐Silva, P., Pimentel, M., et al. (2012) · Microbial Drug Resistance · doi:10.1089/mdr.2012.0025 · Cited by 73 · cited 1×
“In the case of staphylococcal phage endolysins, similar modifications were made to overcome solubility problems [53,54].”
BackgroundSelf-citationThe lytic enzyme of the Pseudomonas phage φ6. Purification and biochemical characterization
Caldentey, J., & Bamford, D. H. (1992) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(92)90073-m · Cited by 72
Determination of the mode of action of enterolysin A, produced by Enterococcus faecalis B9510
Khan, H., Flint, S., & Yu, P. L. (2013) · Journal of Applied Microbiology · doi:10.1111/jam.12240 · Cited by 71 · cited 1×
“Interestingly, this domain is responsible for the PG-degrading activity of the bacteriolysins lysostaphin and enterolysin A [24,25], which also act from without and on actively growing cells.”
BackgroundCheng, M., Zhang, Y., Li, X., Liang, J., Hu, L., Gong, P., Zhang, L., Cai, R., Zhang, H., Ge, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10755-7 · Cited by 71 · cited 1×
“faecalis [110] and more recently the Gram-negative pathogens P.”
BackgroundRodríguez‐Rubio, L., Martínez, B., Zhou, Y., Rodríguez, A., Donovan, D. M., & García, P. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-138 · Cited by 70 · cited 3×
“aureus clinical isolates after 20 min exposure, including methicillin-resistant strains [32,33].”
BackgroundZhang, L., Li, D., Li, X., Hu, L., Cheng, M., Xia, F., Gong, P., Wang, B., Ge, J., Zhang, H., et al. (2016) · Scientific Reports · doi:10.1038/srep29344 · Cited by 70 · cited 1×
“single doses of LysGH15 (50 μg/mouse) were sufficient to protect mice against lethal systemic MRSA infections [103,116].”
BackgroundXia, F., Li, X., Wang, B., Gong, P., Xiao, F., Yang, M. F., Zhang, L., Song, J. I., Hu, L., Cheng, M., et al. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.02581-15 · Cited by 67
Oliveira, H., Pinto, G., Oliveira, A., Oliveira, C., Faustino, M. A., Briers, Y., Domingues, L., & Azeredo, J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7858-0 · Cited by 66 · cited 1×
“Although the OM of Gram-negative bacteria is generally viewed as a barrier that blocks access to the CW of exogenously-added enzymes, several examples of endolysins that spontaneously cross the OM and exert lytic activity were reported [21,62,63,119,120].”
BackgroundSelf-citationMorita, M., Tanji, Y., Orito, Y., Mizoguchi, K., Soejima, A., & Unno, H. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02587-x · Cited by 63 · cited 2×
“Although the OM of Gram-negative bacteria is generally viewed as a barrier that blocks access to the CW of exogenously-added enzymes, several examples of endolysins that spontaneously cross the OM and exert lytic activity were reported [21,62,63,119,120].”
BackgroundOechslin, F., Daraspe, J., Giddey, M., Moreillon, P., & Resch, G. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01701-13 · Cited by 62 · cited 1×
“In some cases, stationary-phase cells were shown to be less susceptible to the enzymes’ lytic action, probably due to cell envelope structural or chemical modification of the PG [65,92].”
BackgroundLood, R., Raz, A., Molina, H., Euler, C. W., & Fischetti, V. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00115-14 · Cited by 60
Takáč, M., & Bläsi, U. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2934-2940.2005 · Cited by 59 · cited 1×
“aureus clinical isolates after 20 min exposure, including methicillin-resistant strains [32,33].”
Fernandes, S., & São‐José, C. (2016) · Molecular Microbiology · doi:10.1111/mmi.13448 · Cited by 59
Self-citationWang, Z., Kong, L., Liu, Y., Fu, Q., Cui, Z., Wang, J., Ma, J., Wang, H., Yan, Y., & Sun, J. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.00380-18 · Cited by 57
Rashel, M., Uchiyama, J., Takemura, I., Hoshiba, H., Ujihara, T., Takatsuji, H., Honke, K., & Matsuzaki, S. (2008) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2008.01152.x · Cited by 56 · cited 1×
“Studies have also demonstrated the bifunctional lytic activity of phiMR11 VAL, bearing cysteine, histidine-dependent amidohydrolase/peptidase and lysozyme activities, by purifying each domain as recombinant proteins [34].”
BackgroundPoonacha, N., Nair, S., Desai, S. N., Tuppad, D., Hiremath, D., Mohan, T., Vipra, A. A., & Sharma, U. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00457-17 · Cited by 48 · cited 1×
“Additionally, VALs have been shown to synergize with endolysins and antibiotics [39,40].”
BackgroundThe structural peptidoglycan hydrolase gp181 of bacteriophage φKZ
Briers, Y., Анатольевич, М. К., Chertkov, O. V., Nekrasov, A., Mesyanzhinov, V. V., Volckaert, G., & Lavigne, R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.102 · Cited by 47 · cited 1×
“Moreover, ECDs from VALs may present increased thermostability when compared to those derived from endolysins [32,37,42,71], which may result in prolonged shelf life.”
BackgroundVouillamoz, J., Entenza, J. M., Giddey, M., Fischetti, V. A., Moreillon, P., & Resch, G. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.020 · Cited by 46
Chopra, S., Harjai, K., & Chhibber, S. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.08.003 · Cited by 45
Oliveira, A., Leite, M. F. R., Kluskens, L., Santos, S. R. B., Melo, L. D. R., & Azeredo, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132095 · Cited by 45
Self-citationThe Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa
Gilmer, D. B., Schmitz, J. E., Thandar, M., Euler, C. W., & Fischetti, V. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169180 · Cited by 44 · cited 1×
“This data is useful to compare enzymes’ performance with antibiotics, which are routinely tested this way, providing also a starting point for setting doses to be used in in vivo assays [77].”
MethodShared Catalysis in Virus Entry and Bacterial Cell Wall Depolymerization
Cohen, D. N., Sham, Y. Y., Haugstad, G. D., Xiang, Y., Rossmann, M. G., Anderson, D. L., & Popham, D. L. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.02.001 · Cited by 32 · cited 1×
“In Gram-positive hosts, VALs from lactococcal phages Tuc2009 and TP901-1 and Bacillus subtilis phages SP-β and phi29 were tested and proved to degrade the bacterial CW [30,31].”
BackgroundStability analysis of the bacteriophage ϕKMV lysin gp36C and its putative role during infection
Briers, Y., Lavigne, R., Plessers, P., Hertveldt, K., Hanssens, I., Engelborghs, Y., & Volckaert, G. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6183-7 · Cited by 31
Proença, D., Leandro, C., García, M., Pimentel, M., & São‐José, C. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6483-7 · Cited by 30 · cited 4×
“[43] generated a chimeric protein (EC300) harboring the M23 ECD of the VAL Orf73 and the CBD of the endolysin Lys170, both from the E.”
BackgroundInfluentialSelf-citationTang, F., Li, D., Wang, H., Ma, Z., Lu, C., & Dai, J. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.02300-15 · Cited by 27
Screw Motion Regulates Multiple Functions of T4 Phage Protein Gene Product 5 during Cell Puncturing
Nishima, W., Kanamaru, S., Arisaka, F., & Kitao, A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja204451g · Cited by 25 · cited 1×
“coli phage T4, respectively) [27] but can also be internal capsid proteins (e.”
BackgroundChemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract
Corsini, B., Díez‐Martínez, R., Aguinagalde, L., González‐Camacho, F., García‐Fernández, E., Letrado, P., García, P., & Yuste, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02212-17 · Cited by 25
Rodríguez‐Rubio, L., Quiles‐Puchalt, N., Martínez, B., Rodríguez, A., Penadés, J. R., & García, P. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01388-13 · Cited by 20 · cited 1×
“coli phage T7 showed to be dispensable for phage infection in the lab suggests that they may confer an advantage only under certain physiological conditions [13,14].”
BackgroundSaravanan, S. R., Paul, V. D., George, S. E., Sundarrajan, S., Kumar, N., Hebbur, M., Kumar, N., Veena, A., Maheshwari, U. T., Appaiah, C. B., et al. (2013) · Bacteriophage · doi:10.4161/bact.26564 · Cited by 16 · cited 1×
“Moreover, ECDs from VALs may present increased thermostability when compared to those derived from endolysins [32,37,42,71], which may result in prolonged shelf life.”
BackgroundOliveira, A., Leite, M. F. R., Kluskens, L., Santos, S. R. B., Melo, L. D. R., & Azeredo, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136331 · Cited by 8
Self-citation
Cited by
The global preclinical antibacterial pipeline
Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0288-0 · Cited by 738
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Phage therapy: Current status and perspectives
Górski, A., Międzybrodzki, R., Węgrzyn, G., Jończyk‐Matysiak, E., Borysowski, J., & Weber‐Dąbrowska, B. (2020) · Medicinal Research Reviews · doi:10.1002/med.21593 · Cited by 159
“Apart from using whole bacteriophages as therapeutic agents, employment of purified phage‐encoded enzymes responsible for destruction of bacterial cell envelope, particularly peptidoglycan, might be an alternative.(16) Such an approach might overcome regulatory challenges, as the therapeutic agent would not be the who…”
Background
Metadata
- Authors
- Oliveira, H., São-José, C., & Azeredo, J.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2018-05-29
- Volume
- 10
- Issue
- 6
- Pages
- 292
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2807288737
- Cited by
- 170
- References
- 120
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.